Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight Licenses Diabetes Meta-Database to Undisclosed Biotech

NEW YORK (GenomeWeb News) — Pharsight has licensed its public-source type II diabetes meta-database to an undisclosed biotechnology company, the informatics shop said today.
The deal is the firs time Pharsight has licensed one of its 20 meta-databases, which compare the “simulated” efficacy and safety of candidate drugs against those of existing drugs, the company said.
According to Pharsight, the drug maker plans to use the database to build quantitative models of the “competitive landscape” for oral diabetes treatments that will “help inform clinical program decision-making” for compounds.
In a statement, Pharsight said its diabetes meta-database comprises clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments, and more than 30 clinical endpoints.
Financial details of the deal were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.